Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine ...
The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...
Recent studies reveal that triplet therapies significantly enhance progression-free survival in patients with endocrine-resistant breast cancer.
MedPage Today on MSN
De-Escalating Bone-Modifying Therapy Safe, Effective in Metastatic Breast Cancer
BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for ...
MedPage Today on MSN
Add-On Radioligand Therapy Slows Metastatic Hormone-Sensitive Prostate Cancer
Patients with metastatic hormone-sensitive prostate cancer (mHSPC) lived significantly longer without disease progression ...
The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback